Regulatory Moderna flu vaccine wins unanimous support from FDA panel BioPharma DiveThe endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year.Infectious DiseaseRead full story pharminent June 18, 2026 (Last updated: June 19, 2026) BioPharma Dive The endorsement of an advisory committee positions Moderna to complete a dramatic turnaround for a shot the FDA declined to review earlier this year. Infectious Disease Read full story Post navigation Previous: MSD takes on Pfizer’s Prevnar with new Capvaxive approvalNext: FDA’s new voucher program hints at broader policy agenda, making many ‘uncomfortable’ Related Stories Regulatory Ultragenyx wins FDA approval for first treatment targeting root cause of GSDIa pharminent August 20, 2026 Regulatory Regeneron wins FDA approval to challenge Ipsen for rare bone disease market pharminent August 20, 2026 Regulatory FDA grants accelerated approval to Ultragenyx’s Genglycos gene therapy pharminent August 20, 2026
